LLY

762

-0.13%↓

JNJ

175.33

-1.02%↓

ABBV

220.83

+0.35%↑

UNH

339.31

-0.35%↓

AZN

76.87

-1.06%↓

LLY

762

-0.13%↓

JNJ

175.33

-1.02%↓

ABBV

220.83

+0.35%↑

UNH

339.31

-0.35%↓

AZN

76.87

-1.06%↓

LLY

762

-0.13%↓

JNJ

175.33

-1.02%↓

ABBV

220.83

+0.35%↑

UNH

339.31

-0.35%↓

AZN

76.87

-1.06%↓

LLY

762

-0.13%↓

JNJ

175.33

-1.02%↓

ABBV

220.83

+0.35%↑

UNH

339.31

-0.35%↓

AZN

76.87

-1.06%↓

LLY

762

-0.13%↓

JNJ

175.33

-1.02%↓

ABBV

220.83

+0.35%↑

UNH

339.31

-0.35%↓

AZN

76.87

-1.06%↓

Search

Design Therapeutics Inc

Открыт

6.16 2.84

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

5.86

Макс.

6.16

Ключевые показатели

By Trading Economics

Доход

-1.4M

-19M

Рентабельность продаж

-2,321.599

Сотрудники

57

EBITDA

-1.3M

-22M

Рекомендации

By TipRanks

Рекомендации

Нейтрально

Прогноз на 12 месяцев

-14.53% downside

Рыночная статистика

By TradingEconomics

Рыночная капитализация

109M

334M

Предыдущая цена открытия

3.32

Предыдущая цена закрытия

6.16

Техническая оценка

By Trading Central

Уверенность

Very Strong Bearish Evidence

Design Therapeutics Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

17 сент. 2025 г., 23:01 UTC

Приобретения, слияния, поглощения

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid -- Update

17 сент. 2025 г., 22:48 UTC

Приобретения, слияния, поглощения

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid

17 сент. 2025 г., 21:59 UTC

Отчет

Cryptocurrency-Exchange Bullish Swings to Profit in First Report as Public Company

17 сент. 2025 г., 23:44 UTC

Обсуждения рынка

Nikkei May Rise as Yen Weakens -- Market Talk

17 сент. 2025 г., 23:39 UTC

Обсуждения рынка

Gold Rises Amid Prospects of Further Fed Rate Cuts -- Market Talk

17 сент. 2025 г., 22:20 UTC

Приобретения, слияния, поглощения

Santos: XRG Consortium Wouldn't Agree to Appropriate Risk Allocation Between It and Santos Shareholders

17 сент. 2025 г., 22:20 UTC

Приобретения, слияния, поглощения

Santos: XRG Consortium Wouldn't Agree to Acceptable Terms That Protected Value of Transaction

17 сент. 2025 г., 22:20 UTC

Приобретения, слияния, поглощения

Santos Had Expressed Concern to XRG Consortium About Delays in Agreeing to Scheme Implementation Agreement

17 сент. 2025 г., 22:19 UTC

Приобретения, слияния, поглощения

Santos: Consortium Notified Board of Decision to Withdraw Proposal on Weds Evening

17 сент. 2025 г., 22:18 UTC

Приобретения, слияния, поглощения

Santos Confirms XRG Consortium Has Withdrawn Takeover Proposal

17 сент. 2025 г., 21:00 UTC

Отчет

Darden Restaurants to Report Earnings. Why the Olive Garden Parent Is Expected to Stay Strong. -- Barrons.com

17 сент. 2025 г., 20:50 UTC

Обсуждения рынка

Financial Services Roundup: Market Talk

17 сент. 2025 г., 20:50 UTC

Обсуждения рынка

Basic Materials Roundup: Market Talk

17 сент. 2025 г., 19:59 UTC

Обсуждения рынка

Global Forex and Fixed Income Roundup: Market Talk

17 сент. 2025 г., 19:59 UTC

Обсуждения рынка

Treasury Yields, Dollar Rise as Fed Cuts, Powell Warns of Risks -- Market Talk

17 сент. 2025 г., 19:07 UTC

Обсуждения рынка

Oil Futures Snap Three-Session Winning Streak -- Market Talk

17 сент. 2025 г., 18:43 UTC

Обсуждения рынка

Treasury Yields, Dollar Reverse Course as Powell Talks to Reporters -- Market Talk

17 сент. 2025 г., 18:38 UTC

Обсуждения рынка

U.S. Natural Gas Futures Mixed Ahead of Storage Data -- Market Talk

17 сент. 2025 г., 18:20 UTC

Обсуждения рынка

Gold Dips After Quarter-Point Rate Cut -- Market Talk

17 сент. 2025 г., 18:18 UTC

Обсуждения рынка

Global Forex and Fixed Income Roundup: Market Talk

17 сент. 2025 г., 18:18 UTC

Обсуждения рынка

Treasury Yields, Dollar Fall on Nearly Unanimous Fed Cut -- Market Talk

17 сент. 2025 г., 18:14 UTC

Обсуждения рынка

Oil Slips Some More as Fed Makes Expected 25 Bp Rate Cut -- Market Talk

17 сент. 2025 г., 17:59 UTC

Обсуждения рынка

Soyoil Takes Hit as Traders Consider EPA Proposal -- Market Talk

17 сент. 2025 г., 17:15 UTC

Приобретения, слияния, поглощения

Netflix 'Has Won The Streaming Wars,' Analyst Says. The Stock Is a Buy. -- Barrons.com

17 сент. 2025 г., 17:06 UTC

Приобретения, слияния, поглощения

Walmart Stock Heads for a Record High. The Retailer Could Become a Leader in 'Agentic' AI. -- Barrons.com

17 сент. 2025 г., 16:51 UTC

Отчет

Correct: Exor 1H Net Loss -EUR624M

17 сент. 2025 г., 16:34 UTC

Обсуждения рынка

Global Forex and Fixed Income Roundup: Market Talk

17 сент. 2025 г., 16:34 UTC

Обсуждения рынка

Bank of Canada Ditches Resilience Talk, Plays Up Slowing Growth -- Market Talk

17 сент. 2025 г., 16:25 UTC

Отчет

Wolters Kluwer: July, August Saw a Slight Increase in Organic Growth Compared to 1H

17 сент. 2025 г., 16:23 UTC

Отчет

Wolters Kluwer: Year-to-Date Performance In Line With 2025 Guidance

Сравнение c конкурентами

Изменение цены

Design Therapeutics Inc Прогноз

Целевая цена

By TipRanks

-14.53% падение

Прогноз на 12 месяцев

Средняя 5 USD  -14.53%

Максимум 5 USD

Минимум 5 USD

Основано на мнении 2 аналитиков Wall Street, спрогнозировавших целевые цены для Design Therapeutics Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Нейтрально

2 ratings

0

Покупка

2

Удержание

0

Продажа

Техническая оценка

By Trading Central

3.26 / 3.63Поддержка и Сопротивление

Краткосрочная

Very Strong Bearish Evidence

Среднесрочная

Bearish Evidence

Долгосрочная

Bearish Evidence

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Design Therapeutics Inc

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.
help-icon Live chat